Immunitybio Inc (IBRX) financials · rev $113.3M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Immunitybio Inc (IBRX) rev $113.3M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $113.3M | $14.7M |
| Cost of Revenue | $753.0K | N/A |
| Gross Profit | $112.5M | N/A |
| Operating Income | -$256.0M | -$344.2M |
| Net Income | -$351.4M | -$413.6M |
| EPS (Diluted) | -$0.38 | -$0.62 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $501.9M | $382.9M |
| Current Assets | $314.9M | $184.6M |
| Cash & Equivalents | $88.3M | $143.4M |
| Inventory | $910.0K | $8.27M |
| PP&E | $114.3M | $137.1M |
| Total Liabilities | $1.00B | $871.1M |
| Current Liabilities | $61.8M | $54.9M |
| Short-term Debt | $1.75M | $1.25M |
| Total Debt | $1.75M† | $1.25M† |
| Shareholders' Equity | -$500.5M | -$489.1M |
| Retained Earnings | -$3.73B | -$3.38B |
† Total Debt: Derived from short-term debt only (no total or long-term debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$304.9M | -$391.2M |
| CapEx | $3.85M | $6.89M |
| Investing Cash Flow | -$149.8M | -$12.2M |
| Financing Cash Flow | $400.2M | $281.6M |
| Net Change in Cash | -$54.5M | -$121.9M |
| Free Cash Flow | -$308.8M | -$398.1M |
FAQ
What is IBRX P/E and revenue?
Immunitybio Inc (IBRX) rev $113.3M.
What is IBRX revenue?
Immunitybio Inc last cached revenue is $113.3M (FY2025).
Is IBRX profitable?
Immunitybio Inc last cached net income is -$351.4M (FY2025).
What are IBRX total assets?
Immunitybio Inc last cached total assets are $501.9M (FY2025).
What is IBRX free cash flow?
Immunitybio Inc last cached free cash flow is -$308.8M (FY2025).
Not investment advice. Cached statements, not a live tape.